Bernier LP, Ase AR, Séguéla P. P2X receptor channels in chronic pain pathways. Br J Pharmacol. 2018;175(12):2219–30.

Article  CAS  PubMed  Google Scholar 

North RA. P2X3 receptors and peripheral pain mechanisms. J Physiol. 2004;554(Pt 2):301–8.

Article  CAS  PubMed  Google Scholar 

North RA. P2X receptors. Philos Trans R Soc Lond B Biol Sci. 2016;371(1700):20150427.

Article  PubMed  PubMed Central  Google Scholar 

Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight GE, et al. P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol. 2005;567(Pt 2):621–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burnstock G. Purinergic signalling: therapeutic developments. Front Pharmacol. 2017;8:661.

Article  PubMed  PubMed Central  Google Scholar 

Bonvini SJ, Belvisi MG. Cough and airway disease: the role of ion channels. Pulm Pharmacol Ther. 2017;47:21–8.

Article  CAS  PubMed  Google Scholar 

Yuan M, Ding S, Meng T, Lu B, Shao S, Zhang X, et al. Effect of A-317491 delivered by glycolipid-like polymer micelles on endometriosis pain. Int J Nanomed. 2017;12:8171–83.

Article  CAS  Google Scholar 

Ryan NM, Vertigan AE, Birring SS. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Expert Opin Pharmacother. 2018;19(7):687–711.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fabbretti E. ATP P2X3 receptors and neuronal sensitization. Front Cell Neurosci. 2013;7:236.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davenport AJ, Neagoe I, Bräuer N, Koch M, Rotgeri A, Nagel J, et al. Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers. Sci Rep. 2021;11(1):19877.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein S, Gashaw I, Baumann S, Chang X, Hummel T, Thuß U, et al. First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: tolerability, safety and pharmacokinetics. Br J Clin Pharmacol. 2022;88(10):4552–64.

Article  CAS  PubMed  Google Scholar 

Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, et al. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021;58(5):2004240.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith JA, Kitt MM, Butera P, Smith SA, Li Y, Xu ZJ, et al. Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J. 2020;55(3):1901615.

Article  CAS  PubMed  Google Scholar 

Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020;8(8):775–85.

Article  CAS  PubMed  Google Scholar 

McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, et al. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399(10328):909–23.

Article  PubMed  Google Scholar 

Finger TE, Danilova V, Barrows J, Bartel DL, Vigers AJ, Stone L, et al. ATP signaling is crucial for communication from taste buds to gustatory nerves. Science. 2005;310(5753):1495–9.

Article  CAS  PubMed  Google Scholar 

Friedrich C, Francke K, Gashaw I, Scheerans C, Klein S, Fels L, et al. Safety, pharmacodynamics, and pharmacokinetics of P2X3 receptor antagonist eliapixant (BAY 1817080) in healthy subjects: double-blind randomized study. Clin Pharmacokinet. 2022;61(8):1143–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dicpinigaitis PV, Morice AH, Smith JA, Sher MR, Vaezi M, Guilleminault L, et al. Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study. Lung. 2023;201(3):255–66.

Article  CAS  PubMed  Google Scholar 

Olafuyi O, Parekh N, Wright J, Koenig J. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? Pharmacol Res Perspect. 2021;9(6): e00890.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kadian N, Raju KS, Rashid M, Malik MY, Taneja I, Wahajuddin M. Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. J Pharm Biomed Anal. 2016;126:83–97.

Article  CAS  PubMed  Google Scholar 

Francke K, Chattopadhyay N, Klein S, Rottmann A, Krickau D, van de Wetering J, et al. Preclinical and clinical pharmacokinetics and bioavailability in healthy volunteers of a novel formulation of the selective P2X3 receptor antagonist eliapixant. Eur J Drug Metab Pharmacokinet. 2023;48(1):75–87.

Article  CAS  PubMed  Google Scholar 

Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015;385(9974):1198–205.

Article  CAS  PubMed  Google Scholar 

Morice AH, Kitt MM, Ford AP, Tershakovec AM, Wu WC, Brindle K, et al. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. Eur Respir J. 2019;54(1):1900439.

Article  CAS  PubMed  Google Scholar